JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

JNJ

186.84

-1.13%↓

ABT

123.18

-0.32%↓

TMO

561.96

-1.07%↓

ISRG

540.64

+1.17%↑

DHR

214.37

-0.58%↓

Search

Omnicell Inc

Deschisă

SectorSănătate

33.52 -0.12

Rezumat

Modificarea prețului

24h

Curent

Minim

32.8

Maxim

33.81

Indicatori cheie

By Trading Economics

Venit

13M

5.6M

Vânzări

21M

291M

P/E

Medie Sector

61.08

37.003

Marjă de profit

1.941

Angajați

3,650

EBITDA

42M

30M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+31.81% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

44M

1.4B

Deschiderea anterioară

33.64

Închiderea anterioară

33.52

Sentimentul știrilor

By Acuity

29%

71%

67 / 373 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Omnicell Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 nov. 2025, 22:13 UTC

Câștiguri

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov. 2025, 21:23 UTC

Câștiguri

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov. 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov. 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov. 2025, 21:00 UTC

Câștiguri

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov. 2025, 21:00 UTC

Câștiguri

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov. 2025, 21:00 UTC

Câștiguri

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov. 2025, 20:55 UTC

Câștiguri

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov. 2025, 20:55 UTC

Câștiguri

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov. 2025, 20:55 UTC

Câștiguri

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov. 2025, 20:46 UTC

Câștiguri

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov. 2025, 20:46 UTC

Câștiguri

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov. 2025, 20:45 UTC

Câștiguri

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov. 2025, 20:44 UTC

Câștiguri

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov. 2025, 20:43 UTC

Câștiguri

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov. 2025, 20:42 UTC

Câștiguri

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov. 2025, 20:41 UTC

Câștiguri

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov. 2025, 20:40 UTC

Câștiguri

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov. 2025, 20:39 UTC

Câștiguri

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov. 2025, 20:37 UTC

Câștiguri

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov. 2025, 20:37 UTC

Câștiguri

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov. 2025, 20:37 UTC

Câștiguri

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov. 2025, 20:36 UTC

Câștiguri

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov. 2025, 20:35 UTC

Câștiguri

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov. 2025, 20:35 UTC

Câștiguri

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov. 2025, 20:35 UTC

Câștiguri

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov. 2025, 20:34 UTC

Câștiguri

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov. 2025, 20:33 UTC

Câștiguri

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov. 2025, 14:27 UTC

Câștiguri

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov. 2025, 14:25 UTC

Câștiguri

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparație

Modificare preț

Omnicell Inc Așteptări

Obiectiv de preț

By TipRanks

31.81% sus

Prognoză pe 12 luni

Medie 44.25 USD  31.81%

Maxim 55 USD

Minim 34 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOmnicell Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

4

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

24.23 / 30.44Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

67 / 373 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat